Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 4 publications
Biomarker analyses from a randomized, placebo-controlled, phase IIIb trial comparing bevacizumab with or without erlotinib as maintenance therapy for the treatment of advanced non-small-cell lung cancer (ATLAS).
Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
Published: August 15, 2014
A randomised, double-blind, placebo-controlled trial of trametinib, an oral MEK inhibitor, in combination with gemcitabine for patients with untreated metastatic adenocarcinoma of the pancreas.
Journal: European journal of cancer (Oxford, England : 1990)
Published: December 30, 2013
ATLAS: randomized, double-blind, placebo-controlled, phase IIIB trial comparing bevacizumab therapy with or without erlotinib, after completion of chemotherapy, with bevacizumab for first-line treatment of advanced non-small-cell lung cancer.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: October 09, 2013
A randomized, double-blind, placebo-controlled study to evaluate the effect of repeated oral doses of pazopanib on cardiac conduction in patients with solid tumors.
Journal: Cancer chemotherapy and pharmacology
Published: October 03, 2012
Showing 1-4 of 4
Last Updated: 09/26/2026